Showing 1 - 20 results of 97 for search '"Vāc"', query time: 0.06s Refine Results
  1. 1

    Genome stability of the vaccine strain VAC∆6 by R. A. Maksyutov, S. N. Yakubitskiy, I. V. Kolosova, T. V. Tregubchak, A. N. Shvalov, E. V. Gavrilova, S. N. Shchelkunov

    Published 2022-07-01
    “…This necessitates the development of modern safe live vaccines based on VAC using genetic engineering. We created the VACΔ6 strain by transient dominant selection. …”
    Get full text
    Article
  2. 2

    Use of “ARRIAH-AviFluVac” vaccine in turkeys, geese and ducks by N. V. Moroz, S. V. Frolov, V. N. Irza, L. O. Scherbakova, V. Yu. Kulakov

    Published 2024-09-01
    “…“ARRIAH-AviFluVac” vaccine against H5 avian influenza was demonstrated to be effective for  ducks, geese and turkeys both in the laboratory and production environment. …”
    Get full text
    Article
  3. 3

    Sobre a eficácia da CoronaVac no Twitter: conversações e aspectos políticos by Carina Luisa Ochi Flexor, Gustavo Costa, Vitória Lobo Batista Barros

    Published 2022-12-01
    “…A CoronaVac, desenvolvida no Brasil pelo Instituto Butantan em parceria com a Sinovac, manteve-se em meio às disputas políticas que permearam o modo como o nosso país enfrentou a pandemia da COVID-19. …”
    Get full text
    Article
  4. 4

    Efficacy of BNT162b2 and CoronaVac in patients diagnosed with COVID-19 by Dogan Mustafa, Yilmaz Berna

    Published 2023-06-01
    “…This retrospective observational study is aimed to determine the efficacy of BNT162b2 (Pfizer-BioNTech) and CoronaVac (Sinovac) vaccines against symptomatic or severe disease in COVID-19-diagnosed patients. …”
    Get full text
    Article
  5. 5
  6. 6
  7. 7

    CoronaVac-induced antibodies that facilitate Fc-mediated neutrophil phagocytosis track with COVID-19 disease resolution by Chuang Li, Jie Yu, Rahma Issa, Lili Wang, Mingzhe Ning, Shengxia Yin, Jie Li, Chao Wu, Yuxin Chen

    Published 2025-12-01
    “…To fully define the potential immune correlates of Fc-mediated effector functions, we comprehensively analysed the above Fc-mediated effector functions in two study cohorts. In the CoronaVac vaccinee cohort, individuals without breakthrough infection exhibited higher levels of ADCP and ADNP activities with a greater degree of cross-reactivity compared to those who had breakthrough infection. …”
    Get full text
    Article
  8. 8

    Endovascular Treatment of Right Heart Masses Utilizing the AngioVac System: A 6-Year Single-Center Observational Study by Aashish Katapadi, Lauren Richards, William Fischer, Suhail Q. Allaqaband, Tanvir Bajwa, M. Fuad Jan

    Published 2021-01-01
    “…To describe our institution’s experience with the AngioVac system. Background. Intracardiac and intravascular masses previously required surgical excision, but now, there are a number of minimally invasive options. …”
    Get full text
    Article
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14

    Adverse events and overall health and well-being after COVID-19 vaccination: interim results from the VAC4COVID cohort safety study by Thomas M MacDonald, Andrew Duncan, Amy Rogers, Greg Guthrie, Alex Doney, Steve Morant, Isla Mackenzie, Evelien Rooke, Rebecca Barr, Filippo Pigazzani, Krists Zutis

    Published 2022-06-01
    “…Objectives To describe the incidence of adverse events (AEs), reactogenicity symptoms, menstrual changes and overall self-rated improvement in health and well-being after COVID-19 vaccination.Design VAC4COVID is an ongoing prospective, active observational, post-authorisation cohort safety study (PASS) of UK-approved vaccines for COVID-19 disease.Setting The study is conducted through a secure website (www.vac4covid.com) by MEMO Research, University of Dundee, UK.Participants 16 265 adult (18 years or older) UK residents with a valid email address and internet access.Interventions Any UK-authorised COVID-19 vaccination.Main outcome measures The outcomes reported in this interim analysis include AEs, reactogenicity-type AEs (headache, fatigue, muscle or joint pain, fever, nausea, dizziness or local vaccine reaction), menstrual changes and reported improvement in overall health and well-being.Results 11 475 consented participants (mean age 54.8 years) provided follow-up data between 2 February and 5 October 2021 (mean follow-up duration 184 days), by which date 89.2% of participants had received two vaccine doses. 89.8% of 5222 participants who completed a follow-up questionnaire in the 7 days after any COVID-19 vaccination reported no AEs. …”
    Get full text
    Article
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20